Newsfeed | Navigating EGFR

EGFR Mutation Detection in Whole Slide Images of Non‐Small Cell Lung Cancers Using a Two‐Stage Deep Transfer Learning Approach

Read more about EGFR Mutation Detection in Whole Slide Images of Non‐Small Cell Lung Cancers Using a Two‐Stage Deep Transfer Learning Approach

Background Lung cancer (LC) is the leading cause of cancer death worldwide. Non-small cell lung cancer is the most frequent and includes adenocarcinoma and squamous cell carcinoma. Currently, LC tre 1 Introduction Despite progress in medical research, lung cancer (LC)...

Human Cytomegalovirus in EGFR‐Mutated and Wild‐Type Lung Adenocarcinoma: Detection in Cytological Smears and Associated Peripheral Immune Response

Read more about Human Cytomegalovirus in EGFR‐Mutated and Wild‐Type Lung Adenocarcinoma: Detection in Cytological Smears and Associated Peripheral Immune Response

Diagnostic CytopathologyEarly View ORIGINAL ARTICLE Human Cytomegalovirus in EGFR-Mutated and Wild-Type Lung Adenocarcinoma: Detection in Cytological Smears and Associated Peripheral Immune Response Suzana Harabajsa, Suzana Harabajsa orcid.org/0000-0001-6791-5289 Division of Pulmonary Cytology, Department of Pathology and Cytology, University Hospital Centre Zagreb,...

Noninvasive prediction of EGFR 19Del and 21L858R subtypes in lung adenocarcinoma: a comparative study of logistic regression and decision tree models

Read more about Noninvasive prediction of EGFR 19Del and 21L858R subtypes in lung adenocarcinoma: a comparative study of logistic regression and decision tree models

ObjectiveDespite the increasing interest in radiogenomic prediction, few studies have directly compared the performance of logistic regression and decision t 1 Introduction Lung adenocarcinoma (LUAD), a predominant histological subtype of non-small cell lung cancer (NSCLC), continues to pose a substantial...

Molecular profiling of circulating tumor cells guides effective EGFR inhibitor treatment in advanced hepatocellular carcinoma: a case report

Read more about Molecular profiling of circulating tumor cells guides effective EGFR inhibitor treatment in advanced hepatocellular carcinoma: a case report

Circulating tumor cells (CTCs) hold promise for use in personalized medicine for hepatocellular carcinoma (HCC). Their abundance and molecular characteristic 1 Introduction Hepatocellular carcinoma (HCC) is one of the top three leading causes of cancer-related death worldwide (1). Systemic treatments...

Authors' Reply: Enhancing eGFR Accuracy in Extreme Body Mass Index Groups: Addressing Body Composition and Methodological Heterogeneity

Read more about Authors' Reply: Enhancing eGFR Accuracy in Extreme Body Mass Index Groups: Addressing Body Composition and Methodological Heterogeneity

Authors' Reply: Enhancing eGFR Accuracy in Extreme Body Mass Index Groups: Addressing Body Composition and Methodological Heterogeneity We thank Li et al.1 for their thoughtful letter and to JASN for the opportunity to respond. We agree that body mass index...

Design, synthesis, antiproliferative assessments, and computational studies of new quinolin-2(1H)-ones as dual EGFR/HER-2 inhibitors

Read more about Design, synthesis, antiproliferative assessments, and computational studies of new quinolin-2(1H)-ones as dual EGFR/HER-2 inhibitors

IntroductionA novel series of quinolin‐2(1H)‐one derivative was rationally designed, synthesized, and characterized as potential dual inhibitors of EGFR and Highlights • A series of new Quinoline-based derivatives was designed and synthesised. • The Structures of new compounds were validated by...

Interpreting Rapid eGFR Decline in the Generation 100 Study

Read more about Interpreting Rapid eGFR Decline in the Generation 100 Study

Interpreting Rapid eGFR Decline in the Generation 100 Study We read with interest the recent JASN publication by Hallan et al.1 examining the effects of high-intensity interval training on kidney function in older adults. The trial adds meaningful data to...

Authors' Reply: Interpreting Rapid eGFR Decline in the Generation 100 Study

Read more about Authors' Reply: Interpreting Rapid eGFR Decline in the Generation 100 Study

Authors' Reply: Interpreting Rapid eGFR Decline in the Generation 100 Study We appreciate the feedback on our JASN article “Long-Term Physical Exercise for Preventing CKD in Older Adults: A Randomized Clinical Trial,”1 which has provided us the opportunity to clarify...

Amivantamab Plus Lazertinib Yields OS Advantage in Asia Cohort of MARIPOSA Trial in EGFR-Mutated NSCLC

Read more about Amivantamab Plus Lazertinib Yields OS Advantage in Asia Cohort of MARIPOSA Trial in EGFR-Mutated NSCLC

Amivantamab Plus Lazertinib Yields OS Advantage in Asia Cohort of MARIPOSA Trial in EGFR-Mutated NSCLC Amivantamab and lazertinib combination therapy significantly improved overall survival in EGFR-mutated NSCLC compared to osimertinib in the MARIPOSA trial's Asia cohort. The combination therapy showed...

New Subcutaneous Amivantamab Combo Dosing Schedule Shows Promising Safety and Efficacy in EGFR-Positive NSCLC

Read more about New Subcutaneous Amivantamab Combo Dosing Schedule Shows Promising Safety and Efficacy in EGFR-Positive NSCLC

New Subcutaneous Amivantamab Combo Dosing Schedule Shows Promising Safety and Efficacy in EGFR-Positive NSCLC The combination of subcutaneous amivantamab-vmjw every 4 weeks plus daily oral lazertinib led to a high response rate in patients with previously untreated EGFR-mutated advanced non–small...

Subscribe to Newsfeed